Explore by Specialty
Research
A reliable constant from bench through clinic.
Early-stage research runs on variables you don't want the needle to be one of. Formulations change, targets shift, and protocols get rewritten between one experiment and the next; the delivery system shouldn't be part of what you're troubleshooting. STERiJECT gives that consistency: the same hub, gauge and cannula geometry your team validates on the bench is the one available when the program moves toward the clinic.
The approach
A platform, not a fixed catalogue
Treat STERiJECT as a set of variables to build on rather than a finished part list. Hub geometry, dead space, internal diameter, cannula length and payload-contact surfaces can all be adjusted and evaluated as part of your experimental system, and where the standard configurations don't fit, we'll work with you to build the one that does.
-
01Small molecules
TSK low-dead-space hub options support evaluation of residual volume, delivered-dose accuracy and dose recovery. Defined hub, gauge and length configurations allow the complete syringe–needle system to be controlled across experiments.
-
02High-concentration biologics
High viscosity can increase injection force and contribute to interrupted or prolonged flow. TSK's thin-wall cannula options provide different internal diameters within a selected outer gauge, enabling force–time, pressure and flow performance to be evaluated under representative viscosity and temperature conditions.
-
03Cell Suspensions
Cannula internal diameter, length and flow conditions can influence cell retention and viable-cell dose recovery. TSK offers configurable bore, gauge and length options that can be assessed for total recovery, viability, potency and concentration consistency before a research configuration is fixed.
-
04Retinal gene-therapy vectors
Device-contact materials, adsorption and residual volume can affect vector recovery, genomic titre and post-delivery activity. TSK can help define the hub flow path, cannula geometry, contact materials and coating strategy, creating a controlled configuration for recovery and potency testing and subsequent development.
Why the constant matters
Switching devices between discovery, tox studies and first-in-human work introduces a variable that's easy to miss and hard to explain away later. Building on STERiJECT from the earliest bench work means the delivery system you characterize is the delivery system you carry forward, so when a result changes, you know it's the science, not the syringe.
Platforms
STERiJECT starting points for evaluation
Availability, intended use and regulatory status vary by country and configuration. These feature sets are starting points for a technical discussion, not application recommendations.
| Platform | Hub | Feature set to explore |
|---|---|---|
| VLDS | Ophthalmic low-dead-space | FDA 510(k)-cleared for ophthalmic use; meets USP <789> particulate testing requirements; bacterial endotoxin limit of 0.2 EU/device. Ophthalmic low-dead-space hub with fine-gauge and short-length options. |
| LDS | Low-dead-space | Gauge, length and lumen options; confirm intended use and regional status. |
| HPC | Hard-polymer; 360° thread | Thin-wall Large/Max options; assess connection integrity, pressure response and flow. |
| PRE | Regular | Broad gauge and length range with enlarged-lumen options. |
Next step
Bring your next breakthrough to life
Share the payload, target dose, route and study objective. We can help identify critical variables and evaluate candidate delivery configurations, and build the configuration if it doesn't exist yet.